期刊
BRITISH JOURNAL OF CANCER
卷 86, 期 2, 页码 179-184出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/sj.bjc.6600043
关键词
melanoma; interleukin-2; interferon alpha; chemotherapy
类别
The purpose of this randomized trial was to evaluate the efficacy of combination chemoimmunotherapy compared with chemotherapy alone. A total of 124 patients were randomized to receive intravenous cisplatin (35 mg m(-2), days 1-3), carmustine (150 mg m-2, day 1, cycles 1 and 3 only), dacarbacine (220 mg m-2, days 1-3) and oral tamoxifen (20 mg m-2, daily) in combination with (n=64) or without (n=60) sequential subcutaneous IL-2 and IFN-alpha. In those patients who received sequential immunothenapy, each cycle of chemotherapy was followed by outpatient s.c. IL-2 (10x 10(6) IU m(-2), days 3-5, week 4; 5 x 10(6) IU m(-2), days 1, 3, 5, week 5) and s.c. IFN-alpha (5 x 10(6) IU m(-2), day 1, week 4; days 1, 3, 5, week 5). The overall response rate of patients treated with the combination of chemotherapy and IL-2/IFN-a was 34.3% with seven complete responses (10.9%) and 15 partial responses (23.4%). In patients treated with chemotherapy, only, the overall response rate was 29.9% with eight complete responses (13.3%) and 10 partial responses (16.6%). There was no significant difference in median progression free survival (0 months vs 4 months) and in median overall survival (12 months vs 13 months) for combined chemoimmunotherapy and for chemotherapy, respectively. (C) 2002 The Cancer Research Campaign.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据